| Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications A Wicki, D Witzigmann, V Balasubramanian, J Huwyler Journal of controlled release 200, 138-157, 2015 | 2308 | 2015 |
| Brain drug delivery of small molecules using immunoliposomes J Huwyler, D Wu, WM Pardridge Proceedings of the National Academy of Sciences 93 (24), 14164-14169, 1996 | 914 | 1996 |
| Pharmacological characterization of designer cathinones in vitro LD Simmler, TA Buser, M Donzelli, Y Schramm, LH Dieu, J Huwyler, ... British journal of pharmacology 168 (2), 458-470, 2013 | 822 | 2013 |
| PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application P Grossen, D Witzigmann, S Sieber, J Huwyler Journal of Controlled Release 260, 46-60, 2017 | 542 | 2017 |
| The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies B Poller, H Gutmann, S Krähenbühl, B Weksler, I Romero, PO Couraud, ... Journal of neurochemistry 107 (5), 1358-1368, 2008 | 419 | 2008 |
| Mechanisms of increased bioavailability through amorphous solid dispersions: a review A Schittny, J Huwyler, M Puchkov Drug delivery 27 (1), 110-127, 2020 | 367 | 2020 |
| Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery J Buck, P Grossen, PR Cullis, J Huwyler, D Witzigmann ACS nano 13 (4), 3754-3782, 2019 | 338 | 2019 |
| Drug transport to brain with targeted liposomes A Schnyder, J Huwyler NeuroRx 2 (1), 99-107, 2005 | 337 | 2005 |
| Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation G Fricker, J Drewe, J Huwyler, H Gutmann, C Beglinger British journal of pharmacology 118 (7), 1841-1847, 1996 | 313 | 1996 |
| Engineered nanomaterial uptake and tissue distribution: from cell to organism H Kettiger, A Schipanski, P Wick, J Huwyler International journal of nanomedicine, 3255-3269, 2013 | 295 | 2013 |
| Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake F Campbell, FL Bos, S Sieber, G Arias-Alpizar, BE Koch, J Huwyler, ... ACS nano 12 (3), 2138-2150, 2018 | 272 | 2018 |
| Polyethylenimine (PEI) in gene therapy: Current status and clinical applications J Casper, SH Schenk, E Parhizkar, P Detampel, A Dehshahri, J Huwyler Journal of Controlled Release 362, 667-691, 2023 | 270 | 2023 |
| Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery D Schwab, H Fischer, A Tabatabaei, S Poli, J Huwyler Journal of medicinal chemistry 46 (9), 1716-1725, 2003 | 257 | 2003 |
| Tumor targeting using liposomal antineoplastic drugs J Huwyler, J Drewe, S Krähenbuhl International Journal of Nanomedicine 3 (1), 21-29, 2008 | 248 | 2008 |
| Magnesium sensing via LFA-1 regulates CD8+ T cell effector function J Lötscher, AAM i Líndez, N Kirchhammer, E Cribioli, GMPG Attianese, ... Cell 185 (4), 585-602. e29, 2022 | 247 | 2022 |
| Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood–brain barrier B Poller, J Drewe, S Krähenbühl, J Huwyler, H Gutmann Cellular and molecular neurobiology 30 (1), 63-70, 2010 | 246 | 2010 |
| HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833 J Drewe, H Gutmann, G Fricker, M Török, C Beglinger, J Huwyler Biochemical pharmacology 57 (10), 1147-1152, 1999 | 219 | 1999 |
| The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans CM Hysek, LD Simmler, M Ineichen, E Grouzmann, MC Hoener, ... Clinical pharmacology & therapeutics 90 (2), 246-255, 2011 | 213 | 2011 |
| Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study CM Hysek, LD Simmler, VG Nicola, N Vischer, M Donzelli, S Krähenbühl, ... PloS one 7 (5), e36476, 2012 | 211 | 2012 |
| Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine AJ Grottick, G Trube, WA Corrigall, J Huwyler, P Malherbe, R Wyler, ... The Journal of Pharmacology and Experimental Therapeutics 294 (3), 1112-1119, 2000 | 189 | 2000 |
